Enantioselective Rauhut–Currier-Type Cyclizations via Dienamine Activation: Scope and Mechanism

Eugenia Marqués-López,^{*a,b} Raquel P. Herrera,^{a,b} Timo Marks,^a Wiebke C. Jacobs,^a Mathias Christmann^{*a}

^a TU Dortmund University, Faculty of Chemistry, Otto-Hahn-Straße 6, 44227 Dortmund (Germany).

^b Departamento de Química Orgánica. Instituto de Síntesis Química y Catálisis Homogénea (ISQCH), Universidad de Zaragoza-CSIC, 50009 Zaragoza (Spain).¹

Fax: (+49) 231-755-5363.

E-mails: mmaamarq@unizar.es, mathias.christmann@tu-dortmund.de

Received: The date will be inserted once the manuscript is accepted.

Abstract:

This Feature Article describes our mechanistic studies in organocatalytic Rauhut–Currier-type reactions and some applications in target-oriented synthesis. The developed approach involves the cyclization of two tethered Michael acceptors via dienamine intermediates and leads to highly functionalized cycloalkenes. The utility of these intermediates is further demonstrated by the synthesis of biologically important targets, such as optically active iridoid derivatives.

- 1 Introduction
- 2 Organocatalytic Cyclization of Tethered α,β -Unsaturated Carbonyl Compounds – Synthesis of Cyclopentene Derivatives
 - 2.1 Mechanistic Proposal
 - 2.1.1 ESI-HRMS Measurements
 - 2.1.2 NMR-Experiments
 - 2.1.3 Complementary Reactivity
 - 2.2 Synthetic Applications
- 3 Organocatalytic Cyclization of Tethered α,β -Unsaturated Carbonyl Compounds – Synthesis of Cyclohexene Derivatives
- 4 Conclusions

Key words: asymmetric synthesis, organocatalysis, dienamine activation, Rauhut–Currier reaction, Michael addition, reaction mechanisms.

1 Introduction

The development of asymmetric transformations exerts considerable leverage on the efficiency of target-oriented syntheses.² To this end, organocatalysis was shown to be a powerful alternative to metal-based and enzymatic catalysis.^{3,4} Within the field, aminocatalysis is probably the most explored area, thus, a great variety of primary and secondary chiral amines have been applied successfully to the synthesis of drugs and natural products.^{4c,5,6} In this respect, enamine⁷ and iminium ion⁸ activation, have become an indispensable strategy in the enantioselective α -⁹ and β -¹⁰ functionalization of carbonyl compounds. More recently, dienamine activation has gained attention for its synthetic potential.^{11,12} Nevertheless, only a small number of examples have appeared since the original work of Jørgensen and Hong, where the electrophilic reactivity of α,β -unsaturated aldehydes is inverted by conversion into a nucleophilic species.¹³ Dienamine intermediates exhibit ambivalent reactivity

(Figure 1). Accordingly, they can be functionalized by suitable electrophiles in the α -¹⁴ and γ -position.^{15,16} In addition, dienamines can be employed as an electron-rich diene in regular Diels–Alder-type reactions,¹⁷ as well as dienophiles in aza-Diels–Alder reactions with inverse electron demand.^{18,19}

Figure 1 Dienamines as chemical chameleons.

The classical Rauhut–Currier (RC) reaction, also known as vinylogous Morita–Baylis–Hillman (MBH) reaction, involves the addition of an enolate generated in situ from a Michael acceptor (RC donor) to a second Michael acceptor (RC acceptor) (Scheme 1), while in the MBH reaction the acceptor is a carbonyl group. In the area of dienamine catalysis our group recently reported an α -alkylation of α,β -unsaturated aldehydes, affording Rauhut–Currier-type products in a mechanistically distinct reaction pathway.^{14a}

Scheme 1 General scheme for Morita–Baylis–Hillman (MBH) and Rauhut–Currier (RC) reactions.

Despite the obvious utility of the RC reaction for the formation of new C–C bonds, only scarce examples of this reaction can be found in the years after its discovery in 1963.^{20,21} This is in contrast with the well-studied MBH reaction.²² However, the situation has changed in the last years, and an analysis of the

recent literature indicates that the RC reaction is gathering increasing attention from several research groups.

A transannular version of the RC reaction was developed by Moore in 1999.²³ Later Krische²⁴ and Roush²⁵ investigated the intramolecular RC reaction using alkyl phosphines as nucleophilic catalysts. More recently, Miller,²⁶ Wu,²⁷ Gu and Xiao,²⁸ Sasai,²⁹ Shi³⁰ and Chi³¹ have reported efficient enantioselective versions of the intramolecular RC reaction using nucleophilic organocatalysts (chiral phosphines or amines), bifunctional acid/base catalysis, or combinations of nucleophilic activation and hydrogen bonding catalysis.^{32,33} Further progress has been accomplished in the challenging intermolecular RC reaction via asymmetric organocatalysis.^{34,35}

Highly functionalized cycloalkenes are important synthesis targets, as they are frequent substructure in biologically active molecules.³⁶ Substituted cyclopentenones are frequently found in the iridoid class of natural products,³⁷ which are widely distributed among plants and insects (Figure 2).³⁸ In plants, iridoid glucosides are of particular interest as some of them exhibit pharmacological activity, while others are intermediates in the biosynthesis of alkaloids.³⁹

Figure 2 Selected iridoids from insect defensive secretions.

There is evidence for the involvement of the RC reaction in the biosynthesis of natural products such as spinosyn A, a tetracyclic polyketide-derived insecticide from *Saccharopolyspora spinosa*. The enzyme SpnL was identified as responsible for the final cross-bridging step that completes the tetracyclic core of spinosyn A in a manner consistent with a Rauhut–Currier reaction.⁴⁰ RC-type processes can be also invoked to explain the biosynthetic formation of some iridoid monoterpenes in insects, such as chrysomelidial (Scheme 2).⁴¹ A possible biosynthetic pathway suggests the formation of a dienamine intermediate that could be formed by condensation of an aldehyde function with an amino group of an enzyme. This intermediate could undergo an inverse electron-demand hetero Diels–Alder reaction providing the *cis*-fused plagiodial skeleton.

Hydrolysis and isomerization then leads to plagiodial and chrysomelidial, respectively.

Scheme 2 Mechanistic hypothesis for the biosynthesis of plagiodial and chrysomelidial in insects.

Herein, we report our recent advances in the development of a mechanistically distinct Rauhut–Currier reaction using dienamine activation.^{14a} Additional experiments confirm the important role of the β -methyl group on the substrates. Mechanistic studies also provided insight into the potential mechanism proposed for this reaction. The novelty, operational simplicity and the applicability to the synthesis of optically active iridoid derivatives as biologically relevant targets, renders this methodology a useful addition to conventional RC protocols.

As described in our previous communication,^{14a} we began our investigation with the optimization of different reaction parameters such as catalyst, temperature, concentration, acid additive or solvent using ketoaldehyde **2a** as model substrate for the cyclization (Scheme 3).

Scheme 3 Model reaction.

In an initial screening of different chiral secondary amines as organocatalysts (**I-VIII**, Scheme 3), the steric bulk of the silyl and the aryl group were found to have a positive effect on the enantioselectivity of this process, however the use of very bulky catalysts resulted in poor reactivity. Thus, as a compromise between both reactivity and enantioselectivity, **IV** was identified as the most appropriate catalyst. We were also pleased to observe that the use of an acid additive such as acetic acid or benzoic acid,⁴² increased the reaction rate without affecting the enantioselectivity. After a study of different solvents and reaction temperatures, the best results were obtained in dichloromethane at room temperature. Other experiments, including the addition of H₂O, variation of the concentration, or slow addition of a solution of the starting material to the reaction mixture using a syringe pump, did not lead to any improvement. We then extended the method to several substrates and we also demonstrated its applicability carrying out an enantioselective synthesis of (*R*)-rotundial (Figure 2),^{14a} a potent natural mosquito repellent isolated from

the plant *Vitex rotundifolia*.⁴³ To the best of our knowledge this constituted the first organocatalytic enantioselective synthesis of (*R*)-rotundial in 25% overall yield, after 6 steps, and with good enantioselectivity (86% ee).⁴⁴

2 Organocatalytic Cyclization of Tethered α,β -Unsaturated Carbonyl Compounds – Synthesis of Cyclopentene Derivatives

Furthermore, we investigated the scope of the cyclization under the optimized reaction conditions [**IV** · AcOH (20 mol%), CH₂Cl₂, r.t.], furnishing the corresponding derivatives **1a-m** in good yields and high enantioselectivities (Scheme 4),⁴⁵ starting from an extended set of substrates **2a-m** that was derived from double homologation of dialdehydes such as succinaldehyde or from commercially available sources such as geranyl acetate.

Scheme 4 Substrate scope. ^[a] Results published in our previous communication. ^[b] After one recrystallization.

These results clearly demonstrate the flexibility of our methodology for introducing differently substituted carbonyl compounds such as aldehydes, aliphatic ketones, electron rich and electron poor aromatic ketones, and other groups such as nitroalkenes. We noted that the electronic properties at the RC acceptor strongly influence the reaction rate and the enantioselectivity of this process. Higher reaction rates can be achieved using Michael acceptors bearing

substituents with electron-withdrawing groups (**1k-m**) whereas significantly lower reaction rates were observed with electron-donating substituents (**1i**).^{14a} The use of α,β -unsaturated alkyl ketones as RC acceptor affords the final adduct in high enantioselectivity with moderate to good yield (**1a,g**), unfortunately bulkier alkyl groups such as *t*Bu (**1h**) lead to a lower yield but with good enantioselectivity. It was possible to employ another Michael acceptor

such as nitroalkenes but the reaction proceeded with lower enantioselectivity (**1j**).^{14a} In general, we have observed that prolonged reaction times led to reduced yields. In this respect, the formation of by-products is the major cause for that reduction, and may be attributed to the instability of aldehyde group.

Interestingly, when the substrate lacks a methyl group in the β -position of the RC donor aldehyde (**1b,d,f**), the results are inferior. Thus, the presence of this methyl group appears to be critical for the success of the process, in terms of both reactivity and enantioselectivity. Therefore and as previously suggested, the methyl group should play an important role in the mechanism of the reaction.

The absolute configuration of the product was determined to be *R* by comparison of the optical rotation of rotundial (**1c**) with that reported in the literature,⁴⁴ and further confirmed by X-ray analysis of compound **1m**.^{14a} The *R* configuration of the stereogenic center created by the dienamine catalysis was established and assumed for all products obtained (**1a-m**).

2.1 Mechanistic Proposal

In our previous report, we proposed the catalytic cycle shown in Scheme 5.^{14a} The first step is the condensation of the substrate **2** with the catalyst **IV**.⁴⁶ The resulting iminium ion **3** possibly exists in an equilibrium with the dienamines **4** and **4'**.^{13b,47} In this case, the reaction is completely α -selective, probably due to steric reasons. The dienamine reacts as an enamine adding to the RC acceptor in an intramolecular Michael reaction leading to intermediate **5**. It is worth mentioning that a mechanism proceeding through a [4+2]-cycloaddition of a dienamine intermediate was proposed by Boland for the biosynthesis of chrysomelidial and plagiodial as depicted in Scheme 2,⁴⁷ and can be not ruled out completely in this case, although the corresponding bicyclic intermediate **9** has not been detected in our process (Scheme 5). Traces of compound **8** resulting from the hydrolysis of intermediate **5**, have been observed by ¹H NMR.⁴⁸ It should be noted that each step in the catalytic cycle is reversible and proton abstraction (**5** $\rightarrow$ **6**) and reprotonation (**6** $\rightarrow$ **5**) could easily lead to *trans*-**5**. Presumably, hydrolysis of **5** to **8** is slow; therefore, protonation of **6** in the γ -position leads to iminium ion **7**, and final hydrolysis releases the product **1** and regenerates the catalyst **IV**.

Scheme 5 Mechanistic hypothesis.

Based on our mechanistic proposal, we hypothesized that the β -methyl substituent in intermediate **4** could lower the relative energy of the required 3*Z*-configu-

ration and its *E*-isomer for the following cyclization step (Scheme 5). In contrast, competitive side reactions, at the γ -position, could take place in

absence of the methyl group, explaining the poor yield obtained for these substrates (**2b,d,f**). Moreover, the more favorable 3*E*-dienamine configuration cannot engage in the cyclization step.

In order to show that the double bond configuration in the enal starting material **2** is inconsequential for the selectivity of the reaction, an experiment with compound **2Z-2a** was performed (Scheme 6). In this case, the same absolute configuration of compound **1a** was obtained as the major one, with a similar yield in comparison with the experiment carried out with *E*-isomer (3 h, 53%, 94% *ee* vs 5 h, 63%, 91% *ee*). This observation could be explained if we assume that the *2Z*-isomer and the *2E*-isomer converge into the same dienamine **4** (Scheme 5).

Scheme 6 Studying the influence of the double bond configuration of the enal starting material.

In order to support our mechanistic model and some of the proposed intermediates, we carried out HRMS and deuterium labeling experiments.

2.1.1 ESI-HRMS Measurements

We performed ESI-HRMS measurements using mixtures of aldehyde **2m** and catalyst **IV** in order to find evidence for intermediates where the catalyst is covalently bound to the substrate.⁴⁹ We could identify some mass peaks corresponding to different species involved in the mechanistic proposal in Scheme 5, such as the starting material **2m** (*m/z* 263), the final product **1m** (*m/z* 263), and the catalyst **IV** (*m/z* 326), as well as other intermediates in the catalytic cycle, all with the same mass, for example **4m** and **4'm** (*m/z* 570) (Figure 3). We were not able to detect intermediate **10** corresponding to the double condensation of the catalyst with both carbonyl groups.⁵⁰ This fact was expected due to the low tendency for catalyst **IV** to activate the hindered ketone moiety.³ However, absence of evidence is not evidence of absence and thus the existence of such a possibly short-lived intermediate cannot be ruled out. Interestingly, the mass of the corresponding oxazolidine **11** (hemiaminal between substrate **2m** and catalyst **IV**) was found (*m/z* 498), which is formed in situ after cleavage of the TMS group of the catalyst **IV** to give the free alcohol **12**, detected also by HRMS (*m/z* 254) (Figure 4). This would explain the relatively high catalyst loading required (20 mol%), for this process. The measured and calculated high resolution masses of the species are given in Table 1. These results support the reactive species given in our mechanistic hypothesis.

Figure 3 ESI-HRMS spectrum of the crude reaction mixture after five minutes.

Figure 4 Oxazolidine **11** and alcohol free catalyst **12**.

Table 1 HRMS (ESI) analysis of the detected intermediates.

Species	Mass (calcd)	Mass (found)	Formula	Error (ppm)
[2m +H] ⁺				
[1m +H] ⁺	263.08333	263.08351	C ₁₅ H ₁₆ O ₂ Cl	0.68311
[IV +H] ⁺	326.19347	326.19369	C ₂₀ H ₂₈ ONSi	0.66807
[4m +H] ⁺	570.25896	570.25824	C ₃₅ H ₄₁ O ₂ NCISi	-1.26884
[11 +H] ⁺	498.21943	498.21906	C ₃₂ H ₃₃ O ₂ NCl	-0.75845
[12 +H] ⁺	254.15394	254.15424	C ₁₇ H ₂₀ ON	1.16840

2.1.2 NMR Experiments

In order to gain further evidence for the intermediacy of the dianamines **4** and **4'**, we performed an NMR experiment, examining the incorporation of deuterium

into the final adduct **11**. First, the cyclization experiment of **21** was performed using deuterated solvent (CD₂Cl₂) and acid (AcOD), and 1 equiv. of D₂O (Scheme 7). Then, incorporation of deuterium was observed at positions (a-c) into the final product **11** by ²H NMR (CHCl₃, 500 MHz), as illustrated in Figure 5.

Scheme 7 Cyclization of **21** in CD₂Cl₂ and the presence of D₂O and AcOD.

In the ²H NMR spectrum, we could observe the incorporation of deuterium in the positions **a** and **b** which is in agreement with the formation of the two dianamines **4** and **4'** as proposed in our mechanistic hypothesis. The observed deuterium incorporation in position **c** is a consequence of the deuteration of the enol **5** to give ketone **6** or a subsequent tautomerization (Scheme 5).

Figure 5 ¹H and ²H NMR spectra of compound d³-**11**.

2.1.3 Complementary Reactivity

It is interesting to compare the reactivity profile of our RC-type reaction with classical RC reactions using nucleophilic phosphines, as previously described by Krische and Roush in 2002 (Scheme 8).^{24,25}

Scheme 8 Rauhut–Currier reaction catalyzed by PMe_3 .

When we applied our optimized conditions to substrate **2a** (route a, Scheme 9), we only observed the formation of compound **1a** in good yield and enantioselectivity. However, with the conditions of Roush (route b, Scheme 9), a complex mixture of products was obtained. While compound **1a** was isolated in only 3% yield, instead **1a'** (6%) was the major product, that was prone to the formation of bicyclic follow-up products **11** (8%) and **12** (8%).

Scheme 9 Aminocatalysis vs PMe_3 as organocatalyst in the cyclization of compound **2a**.

This behavior can be explained with the classical RC activation, which is initiated by a 1,4-addition of the phosphine catalyst (Scheme 10). Due to steric and electronic effects, the β -substituted aldehyde appears to be less electrophilic than the unsubstituted α,β -unsaturated ketone. In this sense the presence of the methyl group in the structure would direct the initial

attack in each case affording complementary chemoselectivity. The mechanism explaining the formation of product **1a'** is depicted in Scheme 10 and is in agreement with the expected Rauhut–Currier mechanism using phosphines as catalysts. The products **13** and **14** are believed to result from an intramolecular aldol addition/elimination.

Scheme 10 Proposed mechanism for the formation of **1a'**.

2.2 Synthetic Applications

In order to showcase the synthetic utility of this strategy, we embarked on the synthesis of the iridoid, mitsugashiwalactone (**17**), as we did previously using this method for the synthesis of rotundial (**1c**).^{14a}

The synthesis of (+)-mitsugashiwalactone (**17**)⁵¹ was accomplished from dialdehyde **1d**. After reduction to the diol **18**,⁵² and oxidation to lactone **19**, the final product was obtained by a 1,4-addition of methyl cuprate (Scheme 11).⁵³ Unfortunately, the product could not be obtained with high enantiomeric excess. It should be noticed that enantioselectivity dropped to 10% ee (from 43% ee) in the oxidation step of **18** to give **19**. The low enantioselectivity in the formation of the cyclic precursor **1d** was limiting the overall enantiomeric excess to 57% ee (Scheme 4).

Scheme 11 Synthesis of (+)-mitsugashiwalactone (**17**).

3 Organocatalytic Cyclization of Tethered α,β -Unsaturated Carbonyl Compounds – Synthesis of Cyclohexene Derivatives

We also studied the formation of six-membered rings, e.g. the trisubstituted cyclohexene derivatives **21a-b** (Scheme 13). The synthesis of the required cyclization precursors (**20a-b**) is outlined in Scheme 12. Hydroxyaldehyde **24** was obtained from commercially available ketonitrile **22** by a HWE olefination followed by a Dibal-H reduction⁵⁴ and subjected to a Wittig olefination with the respective phosphoranylidenes **25**. After IBX oxidation of the allylic alcohols **26**, ketoaldehydes **20a-b** were obtained.

Scheme 12 Synthesis of the substrates **20a-b**.

Unfortunately, when the substrates **20a-b** were submitted to the conditions that were optimized for the formation of corresponding five-membered rings, only poor yields (7-9%) were obtained albeit with good enantioselectivities (76-82% *ee*) (Scheme 13).⁴⁵

Scheme 13 Organocatalytic enantioselective cyclization of **20a-b**.

The lower reaction rates observed in the cyclization reactions leading to 6-membered rings, as well as the

poor yields, may be explained with competing decomposition of the starting material. Interestingly, in this instance we have been able to detect significant amounts of a non-conjugated cyclic product **27** from which we obtained single crystals (Figure 6). An X-ray analysis revealed the relative configuration to be *trans*.^{55,56} This finding provides further support for the intermediacy of the elusive intermediates **5** and **8** from the cyclopentene series (Scheme 5).

Figure 6 X-Ray structure of non-conjugated product **27**.

4 Conclusions

In summary, we have provided new results and mechanistic studies for a better understanding of the enantioselective Rauhut–Currier-type reaction. We have investigated the cyclization of different substrates using dienamine activation affording cyclopentene derivatives in good yields and moderate to high enantioselectivities. The analysis of experiments such as ESI-HRMS or ²H NMR, supports the proposed mechanism and reveals the importance of the methyl group in the β -carbon of the explored substrates. Our procedure represents a useful tool for the asymmetric synthesis of highly functionalized cyclopentenones, such as iridoid derivatives as biologically important targets. The formation of cyclohexene derivatives has been observed but leaves room for further optimization.

All commercially available solvents and reagents were used as received. Analytical thin layer chromatography was performed on Merck TLC silica gel 60 F₂₅₄. Purification of reaction products was carried out by flash chromatography using silica gel (0.040–0.063 mm). NMR spectra were recorded on Bruker DPX300 (300 MHz), DRX400 (400 MHz) or DRX500 (500 MHz) spectrometers. Chemical shifts were reported in the δ scale relative to residual solvent peaks [CHCl₃: δ 7.26 ppm (¹H NMR) and 77.16 ppm (¹³C NMR), CD₃COCD₃: δ 2.05 ppm (¹H NMR) and 206.26 ppm (¹³C NMR) and CD₃OD: δ 3.31 ppm (¹H NMR) and 49.00 ppm (¹³C NMR)]. Chiral HPLC analysis was performed using an Agilent 1200 series HPLC with a diode array detector. Chiral columns include Daicel Chiralpak IA and IB.⁵⁷

Experimental Procedure for Cyclization of Compounds **2** and **20**

In a test tube, to a stirring solution of catalyst (*S*)-**IV** (20 mol%) and acetic acid (20 mol%) in CH₂Cl₂ (1 mL), a solution of **2**⁵⁷ or **20**⁵⁷ in CH₂Cl₂ (2 mL) was

added dropwise, and stirred at r.t. until consumption of the starting material (TLC). Then a saturated aqueous solution of NaHCO_3 (2 mL) was added and the aqueous phase was extracted with CH_2Cl_2 (2 x 2 mL) and Et_2O (2 x 2 mL). The combined organic phases were dried over anhydrous Na_2SO_4 and the solvent was removed under reduced pressure after filtration. The crude product was purified by column chromatography on silica gel affording products **1** or **21**.⁵⁸ The reaction times, yields, and spectral and analytical data for **1** and **21** are as follows.

Organocatalytic Cyclization of **2** – Five Membered Rings

(*R*)-5-(2-Oxopropyl)cyclopent-1-enecarbaldehyde (**1b**)

Following the general procedure starting from **2b** (54.79 mg, 0.36 mmol), after 25 h of reaction, **1b**^{25a} was obtained as yellow oil in 8% yield (4.32 mg), after column chromatography (SiO_2 , pentane/ Et_2O 8:1 → 4:1), 66% *ee*.

HPLC conditions: Daicel Chiralpak IA column (hexane/*i*-PrOH 95:5, flow rate 0.5 mL/min, UV 254.0 nm, $\tau_{\text{minor}} = 17.4$ min; $\tau_{\text{major}} = 20.2$ min).

$[\alpha]_{\text{D}}^{24} +27.1$ ($c = 0.33$, CHCl_3 , 66% *ee*).

(*R*)-5-(2-Oxoethyl)cyclopent-1-enecarbaldehyde (**1d**)

Following the general procedure starting from **2d** (55.00 mg, 0.40 mmol), after 22 h of reaction, **1d** was obtained as colorless oil in 23% yield (12.61 mg) after column chromatography (SiO_2 , pentane/ Et_2O 8:1 → 1:1), 57% *ee* (after derivatization).⁵⁷

IR (KBr film) (cm^{-1}) ν 3020, 2926, 1722, 1677, 1493, 1453, 1216, 754, 669.

^1H NMR (400 MHz, CD_3COCD_3): δ 9.77 (s, 1H), 9.74 (t, $J = 1.5$ Hz, 1H), 7.06-7.04 (m, 1H), 3.34 (br s, 1H), 2.86 (ddd, $J = 17.1$, 4.5, 1.5 Hz, 1H), 2.70-2.50 (m, 2H), 2.41 (ddd, $J = 17.1$, 9.0, 2.0 Hz, 1H), 2.34-2.24 (m, 1H), 1.70-1.62 (m, 1H).

^{13}C NMR (100 MHz, CD_3COCD_3): δ 202.0, 190.3, 155.2, 149.6, 48.2, 37.4, 32.7, 31.0.

GC-EI-MS m/z (%) 67 (92), 81 (75), 94 (100), 120 (50), 138 (3) $[\text{M}]^+$.

GC-EI-HRMS ($[\text{M}]^+$) calcd for $\text{C}_8\text{H}_{10}\text{O}_2$ 138.0671, found 138.0675.

(*R*)-5-(2-Oxo-2-phenylethyl)cyclopent-1-enecarbaldehyde (**1f**)

Following the general procedure starting from **2f** (77.13 mg, 0.36 mmol), after 22 h of reaction, **1f** was obtained as yellow oil in 20% yield (15.43 mg) after column chromatography (SiO_2 , pentane/ Et_2O 8:1), 51% *ee*.

HPLC conditions: Daicel Chiralpak IA column (hexane/*i*-PrOH 90:10, flow rate 0.5 mL/min, UV 254.0 nm, $\tau_{\text{minor}} = 15.9$ min; $\tau_{\text{major}} = 17.8$ min).

$[\alpha]_{\text{D}}^{24} +44.6$ ($c = 1.30$, CHCl_3 , 51% *ee*).

IR (KBr film) (cm^{-1}) ν 2937, 2812, 1677, 1448, 1363, 1282, 1202, 984, 753, 692.

^1H NMR (400 MHz, CDCl_3): δ 9.81 (s, 1H), 8.00-7.98 (m, 2H), 7.57-7.53 (m, 1H), 7.47-7.44 (m, 2H), 6.94-6.92 (m, 1H), 3.72 (dd, $J = 16.5$, 3.0 Hz, 1H), 3.54 (br s, 1H), 2.75 (dd, $J = 16.5$, 10.5 Hz, 1H), 2.71-2.51 (m, 2H), 2.39-2.30 (m, 1H), 1.77-1.69 (m, 1H).

^{13}C NMR (100 MHz, CDCl_3): δ 199.4, 190.0, 154.8, 149.2, 136.9, 133.2, 128.7, 128.3, 42.3, 38.7, 32.4, 30.3.

GC-EI-MS m/z (%) 77 (40), 105 (100), 214 (8) $[\text{M}]^+$.

HPLC-EI-HRMS ($[\text{M}]^+$) calcd for $\text{C}_{14}\text{H}_{14}\text{O}_2$ 214.0988, found 214.0985.

(*R*)-2-Methyl-5-(2-(4-nitrophenyl)-2-oxoethyl)cyclopent-1-enecarbaldehyde (**1g**)

Following the general procedure starting from **2g** (130 mg, 0.72 mmol), after 9 h of reaction, **1g** was obtained as yellow oil in 62% yield (70.00 mg) after column chromatography (SiO_2 , cyclohexane/ EtOAc 3:1), 85% *ee*.

HPLC conditions: Daicel Chiralpak IA column (hexane/*i*-PrOH 90:10, flow rate 0.5 mL/min, UV 254.4 nm, $\tau_{\text{minor}} = 17.0$ min; $\tau_{\text{major}} = 15.1$ min).

$[\alpha]_{\text{D}}^{20} +109.7$ ($c = 1.0$, CHCl_3).

IR (KBr) (cm^{-1}) ν 2975, 2939, 2834, 2757, 1712, 1664, 1631, 1433, 1411, 1378, 1350, 1272, 1190, 1114, 1032, 977, 761, 584, 421.

^1H NMR (400 MHz, CDCl_3): δ 9.97 (s, 1H), 3.41 (br s, 1H), 3.00 (dd, $J = 1.6$, 0.4 Hz, 1H), 2.63-2.55 (m, 1H), 2.51-2.32 (m, 3H), 2.28 (dd, $J = 16.7$, 10.1 Hz, 1H), 2.19-2.10 (m, 1H), 2.13 (s, 3H), 1.53-1.45 (m, 1H), 1.05 (t, $J = 0.8$ Hz, 3H).

^{13}C NMR (400 MHz, CDCl_3): δ 210.9, 188.1, 164.0, 139.5, 46.0, 39.5, 39.0, 35.9, 28.2, 14.4, 7.8.

HPLC-ESI-HRMS ($[\text{M}+\text{H}]^+$) calcd for $\text{C}_{11}\text{H}_{17}\text{O}_2$ 181.25148, found 181.12223.

(*R*)-2-Methyl-5-(2-(4-nitrophenyl)-2-oxoethyl)cyclopent-1-enecarbaldehyde (**1h**)

Following the general procedure starting from **2h** (70.71 mg, 0.34 mmol), after 25 h of reaction, **1h** was obtained in 38% yield (27 mg) after column chromatography (SiO_2 , pentane/ Et_2O 4:1), 75% *ee*.

HPLC conditions: Daicel Chiralpak IA column (hexane/*i*-PrOH 97:3, flow rate 0.5 mL/min, UV 254.4 nm, $\tau_{\text{minor}} = 13.4$ min; $\tau_{\text{major}} = 15.2$ min).

$[\alpha]_{\text{D}}^{20} +92.7$ ($c = 1.03$, CHCl_3).

IR (KBr) (cm^{-1}) ν 2968, 1704, 1662, 1478, 1394, 3380, 1366, 1345, 1283, 1250, 1188, 1063, 1002.

^1H NMR (400 MHz, CDCl_3): δ 9.98 (s, 1H), 3.41 (br s, 1H), 3.07 (dd, $J = 2.0$, 0.4 Hz, 1H), 2.62-2.53 (m, 1H), 2.50-2.37 (m, 2H), 2.22-2.15 (m, 1H), 2.14 (s, 3H), 1.42-1.34 (m, 1H), 1.11 (s, 9H).

^{13}C NMR (400 MHz, CDCl_3): δ 215.2, 188.2, 163.9, 139.8, 44.0, 40.3, 39.4, 39.1, 28.4, 26.4 (3C), 14.5.

HPLC-ESI-HRMS ($[M+H]^+$) calcd for $C_{13}H_{21}O_2$ 209.30464, found 209.15361.

Cyclization of **2a** Using PMe_3 as Organocatalyst

A solution of (2*E*,6*Z*)-3-methyl-8-oxonona-2,6-dienal (**2a**) (59.83 mg, 0.36 mmol) in *tert*-amyl alcohol (3.6 mL) was deoxygenated by bubbling Ar through the solution for 30 min. To the oxygen-free solution was added PMe_3 (7.8 μ L, 0.07 mmol) by μ syringe.^{25a} After 1 h the reaction mixture was treated with an aqueous solution of $NaHSO_4$ (1 M). Then the organic layer was separated and the aqueous layer was extracted with Et_2O (3 x 2 mL). The combined organic phases were washed with an aqueous saturated solution of NaCl, dried over anhydrous Na_2SO_4 and the solvent was removed under reduced pressure after filtration. The crude product was purified by column chromatography (SiO_2 , pentane/ Et_2O 8:1 $\rightarrow$ 1:2) affording products **1a** (3%), **1a'** (6%), **13** (8%) and **14** (8%). The spectral and analytical data for **1a'**, **13** and **14** are as follows.

2-(2-Acetyl-1-methylcyclopent-2-enyl)acetaldehyde (**1a'**)

Yellow oil.

IR (KBr film) (cm^{-1}) ν 3440, 2930, 1708, 1665, 1365, 1264, 1102.

1H NMR (500 MHz, $CDCl_3$): δ 9.69 (dd, $J = 3.2, 1.9$ Hz, 1H), 6.76 (t, $J = 2.8$ Hz, 1H), 2.87 (dd, $J = 15.4, 1.9$ Hz, 1H), 2.70 (dd, $J = 15.5, 3.1$ Hz, 1H), 2.53-2.45 (m, 2H), 2.30 (s, 3H), 1.99 (ddd, $J = 13.0, 8.6, 7.4$ Hz, 1H), 1.83 (ddd, $J = 13.2, 8.2, 5.0$ Hz, 1H), 1.30 (s, 3H).

^{13}C NMR (125 MHz, $CDCl_3$): δ 202.9, 196.9, 149.7, 145.9, 52.6, 47.1, 38.2, 30.5, 27.7, 26.1.

GC-EI-MS m/z (%) 122 (100), 138 (70), 151 (10), 166 (3) $[M]^+$.

GC-EI-HRMS ($[M]^+$) calcd for $C_{10}H_{14}O_2$ 166.0988, found 166.0986.

6-Hydroxy-7a-methyl-5,6,7,7a-tetrahydro-1H-inden-4(2H)-one (**13**)

Yellow oil.

IR (KBr film) (cm^{-1}) ν 3430, 2931, 1774, 1617, 1253, 1151, 1044.

1H NMR (500 MHz, $CDCl_3$): δ 6.51 (t, $J = 2.7$ Hz, 1H), 4.35-4.28 (m, 1H), 2.87 (ddd, $J = 16.7, 5.3, 2.1$ Hz, 1H), 2.59-2.49 (m, 1H), 2.47-2.38 (m, 1H), 2.33-2.20 (m, 2H), 2.03-1.95 (m, 1H), 1.92-1.84 (m, 1H), 1.64-1.60 (m, 2H), 1.08 (s, 3 H).

^{13}C NMR (125 MHz, $CDCl_3$): δ 197.1, 148.0, 137.2, 66.6, 50.1, 47.6, 45.6, 42.4, 30.4, 25.1.

GC-EI-HRMS ($[M]^+$) calcd for $C_{10}H_{14}O_2$ 166.0988, found 166.0993.

7a-Methyl-7,7a-dihydro-1H-inden-4(2H)-one (**14**)

Yellow oil.

IR (KBr film) (cm^{-1}) ν 3447, 2960, 2926, 1688, 1455, 1382, 1261, 1098, 1024.

1H NMR (400 MHz, $CDCl_3$): δ 6.89 (ddd, $J = 10.3, 6.0, 2.3$ Hz, 1H), 6.65 (t, $J = 2.8$ Hz, 1H), 6.12 (ddd, $J = 10.0, 3.0, 1.0$ Hz, 1H), 2.60-2.32 (m, 4H), 2.05 (ddd, $J = 12.5, 6.0, 2.5$ Hz, 1H), 1.88 (dt, $J = 12.5, 9.5$ Hz, 1H), 1.12 (s, 3H).

^{13}C NMR (125 MHz, $CDCl_3$): δ 186.8, 148.5, 146.9, 137.0, 130.5, 46.9, 41.5, 41.2, 30.3, 25.0.

ESI-MS m/z (%) 149 (100) $[M+1]^+$.

GC-EI-HRMS ($[M]^+$) calcd for $C_{10}H_{12}O$ 148.0883, found 148.0875.

Synthesis of (+)-Mitsugashiwalactone (**17**)

(*R*)-4,4a,5,6-Tetrahydrocyclopenta[c]pyran-1(3H)-one (**19**)^{52a,59}

MnO_2 (1.75 g, 20.13 mmol) was added to a solution of diol **18** (159 mg, 1.12 mmol, 43% *ee* (after derivatization)⁵⁷ in $CHCl_3$ (5 mL). The resulting mixture was stirred at 66 °C for 12 h, and then filtered. The solvent was removed under reduced pressure. The crude product was purified by column chromatography (SiO_2 , pentane/ $EtOAc$ 3:1) to afford lactone **19**^{51b} in 71% yield (110 mg) as a light yellow oil.

$[\alpha]_D^{22} = -12.1$ ($c = 1.00$, $CHCl_3$, 10% *ee*) {lit.^{51b} $[\alpha]_D^{31} = -116.6$ ($c = 0.93$, $CHCl_3$, >99% *ee* (HPLC))}.

IR (KBr film) (cm^{-1}) ν 1715, 1628, 1255, 743.

1H NMR (400 MHz, $CDCl_3$): δ 6.99 (d, $J = 2.5$ Hz, 1H), 4.45 (ddd, $J = 11.6, 4.5, 2.0$ Hz, 1H), 4.31 (dt, $J = 11.5, 2.5$ Hz, 1H), 2.97 (br s, 1H), 2.50-2.45 (m, 2H), 2.41-2.34 (m, 1H), 2.10 (br dt, $J = 13.5, 2.5$ Hz, 1H), 1.73-1.58 (m, 2H).

^{13}C NMR (100 MHz, $CDCl_3$): δ 163.5, 145.5, 134.7, 69.7, 42.0, 32.7, 31.7, 30.8.

ESI-MS m/z (%) 93 (27), 111 (33), 139 (100) $[M+H]^+$.

HPLC-EI-HRMS ($[M+H]^+$) calcd for $C_8H_{11}O_2$ 139.07536, found 139.07509.

(4*aR*,7*S*,7*aR*)-7-

Methylhexahydrocyclopenta[c]pyran-1(3H)-one (**17**)^{51b}

To a solution of lithium dimethylcuprate [prepared in situ by mixing CuI (310 mg, 1.63 mmol) in Et_2O (2 mL) and MeLi in Et_2O (2.14 mL, 3.26 mmol, 1.6 M in Et_2O) at -25 °C], lactone **19** (75 mg, 0.54 mmol) in Et_2O (1 mL) was added at -25 °C and stirring at the same temperature for 30 min. Then a saturated aqueous solution of NH_4Cl was added, and the mixture was extracted with Et_2O (3 x 7 mL). The combined organic phases were washed with brine (2 mL), dried over anhydrous $MgSO_4$ and the solvent was removed under reduced pressure after filtration. The crude product was purified by column chromatography (SiO_2 , pentane/ $EtOAc$ 4:1) to afford (+) mitsugashiwalactone (**17**)⁵¹ in 84% yield (70 mg) as colorless oil.

$[\alpha]_{\text{D}}^{20} = +0.6$ ($c = 2.00$, CHCl_3) {lit.^{51b} $[\alpha]_{\text{D}}^{32} = +5.3$ ($c = 0.92$, CHCl_3), $[\alpha]_{\text{D}}^{32} = +6.3$ ($c = 0.96$, CCl_4), $[\alpha]_{\text{D}}^{24} = +4.6$ ($c = 2.00$, CHCl_3), natural^{51a} $[\alpha]_{\text{D}}^{32} = +6.4$ (not described)}.

IR (KBr film) (cm^{-1}) ν 3018, 2956, 2926, 2856, 1723, 1216, 756.

^1H NMR (400 MHz, CDCl_3): δ 4.33 (ddd, $J = 11.1$, 6.6, 3.0 Hz, 1H), 4.20 (ddd, $J = 11.0$, 8.5, 2.5 Hz, 1H), 2.59–2.54 (m, 1H), 2.38 (t, $J = 9.6$ Hz, 1H), 2.26–2.20 (m, 1H), 2.04–2.00 (m, 2H), 1.94–1.90 (m, 1H), 1.57–1.50 (m, 1H), 1.33–1.18 (m, 2H), 1.21 (d, $J = 6.5$ Hz, 3H).

^{13}C NMR (100 MHz, CDCl_3): δ 174.6, 66.9, 50.2, 39.5, 36.2, 34.7, 32.7, 29.2, 19.9.

ESI-MS m/z (%) 109 (55), 155 (100) $[\text{M}+\text{H}]^+$.

HPLC-EI-HRMS ($[\text{M}+\text{H}]^+$) calcd for $\text{C}_9\text{H}_{15}\text{O}_2$ 155.10666, found 155.10635.

Organocatalytic Cyclization of 20 – Six Membered Rings

Following the general procedure starting from **20a** (114.90 mg, 0.04 mmol), after 48 h of reaction, products **21a** (9% yield, 76% *ee*) and **27** (12% yield, >99% *ee*) were obtained after column chromatography (SiO_2 , pentane/ Et_2O 4:1 $\rightarrow$ 2:1); (**21a**:**27** = 24:76, by ^1H NMR of the crude product).

2-Methyl-6-(2-(4-nitrophenyl)-2-oxoethyl)cyclohex-1-enecarbaldehyde (21a)

HPLC conditions: Daicel Chiralpak IA column (hexane/*i*-PrOH 90:10, flow rate 1.0 mL/min, UV 254.4 nm, $\tau_{\text{major}} = 20.4$ min; $\tau_{\text{minor}} = 24.2$ min).

^1H NMR (400 MHz, CDCl_3): δ 10.17 (s, 1H), 8.39–8.24 (m, 4H), 3.36 (dd, $J = 14.6$, 3.0 Hz, 1H), 3.25–3.20 (m, 1H), 2.68 (dd, $J = 14.6$, 11.0 Hz, 1H), 2.31–2.24 (m, 2H), 2.20 (s, 3H), 1.77–1.63 (m, 3H), 1.56–1.48 (m, 1H).

^{13}C NMR (125 MHz, CDCl_3): δ 198.5, 191.0, 159.1, 150.5, 141.2, 136.0, 129.8, 124.0, 43.2, 34.5, 28.7, 25.6, 18.9, 17.4.

EI-MS m/z (%) 94 (100), 150 (80), 259 (85), 270 (50), 287 (10) $[\text{M}]^+$.

GC-EI-HRMS ($[\text{M}]^+$) calcd for $\text{C}_{16}\text{H}_{17}\text{O}_4\text{N}$ 287.1152, found 287.1151.

2-Methyl-6-(2-(4-nitrophenyl)-2-oxoethyl)cyclohex-2-enecarbaldehyde (27)

HPLC conditions: Daicel Chiralpak IB column (hexane/*i*-PrOH 80:20, flow rate 0.5 mL/min, UV 254.4 nm, $\tau_{\text{major}} = 20.6$ min; $\tau_{\text{minor}} = 25.0$ min).

^1H NMR (400 MHz, CDCl_3): δ 9.58 (d, $J = 2.9$ Hz, 1H), 8.32 (d, $J = 8.8$ Hz, 2H), 8.10 (d, $J = 8.8$ Hz, 2H), 5.77 (br s, 1H), 3.09 (dd, $J = 17.6$, 6.5 Hz, 1H), 2.99 (dd, $J = 17.6$, 6.5 Hz, 1H), 2.85–2.77 (m, 1H), 2.72 (br s, 1H), 2.13–2.07 (m, 2H), 1.82–1.74 (m, 1H), 1.73 (br s, 3H), 1.50–1.37 (m, 1H).

EI-MS m/z (%) 94 (100), 150 (80), 259 (85), 270 (40), 287 (10) $[\text{M}]^+$.

GC-EI-HRMS ($[\text{M}]^+$) calcd for $\text{C}_{16}\text{H}_{17}\text{O}_4\text{N}$ 287.1152, found 287.1150.

6-(2-(4-Chlorophenyl)-2-oxoethyl)-2-methylcyclohex-1-enecarbaldehyde (21b)

Following the general procedure starting from **20b** (52.4 mg, 0.19 mmol), **21b** was obtained after 3 d in 7% yield (3.51 mg) after column chromatography (SiO_2 , pentane/ Et_2O 6:1), 82% *ee*.

HPLC conditions: Daicel Chiralpak IA column (hexane/*i*-PrOH 90:10, flow rate 0.5 mL/min, UV 254.4 nm, $\tau_{\text{minor}} = 19.6$ min; $\tau_{\text{major}} = 22.8$ min).

^1H NMR (400 MHz, CDCl_3): δ 10.17 (s, 1H), 8.08 (d, $J = 8.5$ Hz, 2H), 7.45 (d, $J = 8.5$ Hz, 2H), 3.30 (dd, $J = 14.7$, 3.0 Hz, 1H), 3.25–3.20 (m, 1H), 2.60 (dd, $J = 14.7$, 11.2 Hz, 1H), 2.27–2.24 (m, 2H), 2.19 (s, 3H), 1.79–1.53 (m, 3H), 1.54–1.40 (m, 1H).

^{13}C NMR (125 MHz, CDCl_3): δ 198.9, 191.0, 158.6, 139.5, 136.4, 135.2, 130.2, 129.0, 42.6, 34.5, 28.8, 25.5, 18.8, 17.4.

HPLC-ESI-HRMS ($[\text{M}+\text{H}]^+$) calcd for $\text{C}_{16}\text{H}_{18}\text{O}_2\text{Cl}$ 277.09898, found 277.09917.

Supporting Information for this article is available online at <http://www.thieme-connect.com/ejournals/toc/synthesis>.

Acknowledgment

We thank the Fonds der Chemischen Industrie for a Dozentenstipendium (M.C.), the DFG (Priority Program 1179 - Organocatalysis), Spanish Government (CTQ2010-19606-C02-01), the Humboldt Foundation (postdoctoral (E.M.-L.) and experienced researcher (R.P.H.) fellowships). Finally, we thank Dr. Pablo J. Sanz Miguel (TU-Dortmund) [X-ray], Dr. Wolf Hiller (TU-Dortmund) [^2H NMR], and Nina Mészáros (TU-Dortmund) [ESI-HRMS].

References

- (1) New address for E. Marqués-López and R. P. Herrera.
- (2) *Asymmetric synthesis: More methods and applications*; Christmann, M.; Bräse, S., Eds.; Wiley-VCH: Weinheim, 2012.
- (3) For selected reviews on organocatalysis, see for example: (a) Dalko, P. I.; Moisan, L. *Angew. Chem. Int. Ed.* **2004**, 43, 5138. (b) *Asymmetric Organocatalysis*; Berkessel, A.; Gröger, H., Eds.; Wiley-VCH: Weinheim, 2004. (c) *Asymmetric organocatalysis in Acc. Chem. Res.* **2004**, 37 (8), 487; Houk, K. N.; List, B., Eds. (special issue on organocatalysis). (d) Seayed, J.; List, B. *Org. Biomol. Chem.* **2005**, 3, 719. (e) *Enantioselective organocatalysis*; Dalko, P. I., Ed.; Wiley-VCH: Weinheim, 2007. (f) *Organocatalysis in Chem. Rev.* **2007**, 107 (12), 5413; List, B., Ed. (special issue on organocatalysis). (g) Dondoni, A.; Massi, A. *Angew. Chem. Int. Ed.* **2008**, 47, 4638. (h) *Asymmetric organocatalysis; Top Curr. Chem.* **2010**, 291, 1; List, B., Ed. (i) *Fundamentals in organocatalysis. Past, present and future in Curr. Org. Chem.* **2011**, 15 (13), 2082; Herrera, R. P., Ed. (special issue on organocatalysis). (j) Buckley, B. R.; Kimber, M. C.; Slater, N. H. *Annu. Rep. Prog. Chem., Sect. B: Org. Chem.* **2012**, 108, 98. (k) *Science of synthesis, Asymmetric organocatalysis 1, Lewis base and acid catalysts*; List, B., Ed.; Thieme:

- Stuttgart, **2012**. (l) *Science of synthesis, Asymmetric organocatalysis 1, Brønsted base and acid catalysts, and additional topics*; Maruoka, K., Ed.; Thieme: Stuttgart, **2012**. (m) *Comprehensive enantioselective organocatalysis*; Dalko, P. I., Ed.; Wiley-VCH, Weinheim, **2013**.
- (4) For applications of organocatalysis in the synthesis of natural products and non-natural biologically active molecules, see: (a) de Figueiredo, R. M.; Christmann, M. *Eur. J. Org. Chem.* **2007**, 2575. (b) Marqués-López, E.; Herrera, R. P.; Christmann, M. *Nat. Prod. Rep.* **2010**, *27*, 1138. (c) Christmann, M. *Applications of aminocatalysis in target-oriented synthesis in Science of synthesis, Asymmetric organocatalysis 1, Lewis base and acid catalysts*; List, B., Ed.; Thieme: Stuttgart, **2012**, 439. (d) Marqués-López, E.; Herrera, R. P. in *Comprehensive enantioselective organocatalysis*; Dalko, P. I., Ed.; Wiley-VCH, Weinheim, **2013**.
- (5) For reviews on aminocatalysis, see: (a) Palomo, C.; Mielgo, A. *Angew. Chem. Int. Ed.* **2006**, *45*, 7876. (b) Mielgo, A.; Palomo, C. *Chem. Asian J.* **2008**, *3*, 922. (c) Barbas III, C. F. *Angew. Chem. Int. Ed.* **2008**, *47*, 42. (d) Melchiorre, P.; Marigo, M.; Carlone, A.; Bartoli, G. *Angew. Chem. Int. Ed.* **2008**, *47*, 6138. (e) Bertelsen, S.; Jørgensen, K. A. *Chem. Soc. Rev.* **2009**, *38*, 2178. (f) List, B. *Angew. Chem. Int. Ed.* **2010**, *49*, 1730.
- (6) For reviews about organocatalytic reactions catalyzed by chiral primary amines, see: (a) Peng, F.; Shao, Z. *J. Mol. Catal. A*, **2008**, *285*, 1. (b) Xu, L.-W.; Luo, J.; Lu, Y. *Chem. Commun.* **2009**, 1807.
- (7) For reviews, see: (a) Mukherjee, S.; Yang, J. W.; Hoffmann, S.; List, B. *Chem. Rev.* **2007**, *107*, 5471. (b) Phiko, P. M.; Majander, I.; Erkkilä, A. *Top. Curr. Chem.* **2010**, *291*, 29.
- (8) For reviews, see: Erkkilä, A.; Majander, I.; Phiko, P. M. *Chem. Rev.* **2007**, *107*, 5416. (b) Brazier, J. B.; Tomkinson, N. C. O. *Top. Curr. Chem.* **2010**, *291*, 281.
- (9) For reviews on α -functionalization using enamine activation, see for example: (a) Marigo, M.; Jørgensen, K. A. *Chem. Commun.* **2006**, 2001. (b) Guillena, G.; Ramón, D. J. *Tetrahedron: Asymmetry* **2006**, *17*, 1465.
- (10) For reviews on conjugated additions using iminium-ion activation see, for example: (a) Tsogoeva, S. B. *Eur. J. Org. Chem.* **2007**, 1701. (b) Almasi, D.; Alonso, D. A.; Nájera, C. *Tetrahedron: Asymmetry* **2007**, *18*, 299. (c) Vicario, J. L.; Badia, D.; Carrillo, L. *Synthesis* **2007**, 2065.
- (11) For recent reviews on dienamine catalysis, see: (a) Ramachary, D. B.; Reddy, Y. V. *Eur. J. Org. Chem.* **2012**, 865. (b) Christmann, M. *Asymmetric dienamine activation in Asymmetric synthesis: More methods and applications*; Christmann, M.; Bräse, S. Eds.; Wiley-VCH: Weinheim, **2012**, 43.
- (12) For a recent review on trienamine catalysis, see: Kumar, I.; Ramaraju, P.; Mir, N. A. *Org. Biomol. Chem.* **2013**, *11*, 709, and references cited therein.
- (13) For pioneering work, see: (a) Chen, S.-H.; Hong, B.-C.; Su, C.-F.; Sarshar, S. *Tetrahedron Lett.* **2005**, *46*, 8899. (b) Bertelsen, S.; Marigo, M.; Brandes, S.; Dinér, P.; Jørgensen, K. A. *J. Am. Chem. Soc.* **2006**, *128*, 12973. (c) Hong, B.-C.; Wu, M.-F.; Tseng, H.-C.; Liao, J.-H. *Org. Lett.* **2006**, *8*, 2217. (d) Bench, B. J.; Liu, C.; Evett, C. R.; Watanabe, C. M. H. *J. Org. Chem.* **2006**, *71*, 9458. (e) Utsumi, N.; Zhang, H.; Tanaka, F.; Barbas III, C. F. *Angew. Chem. Int. Ed.* **2007**, *46*, 1878.
- (14) (a) Marqués-López, E.; Herrera, R. P.; Marks, T.; Jacobs, W. C.; Könnig, D.; de Figueiredo, R. M.; Christmann, M. *Org. Lett.* **2009**, *11*, 4116. (b) Han, B.; Xiao, Y.-C.; He, Z.-Q.; Chen, Y.-C. *Org. Lett.* **2009**, *11*, 4660. (c) Han, B.; Xiao, Y.-C.; Yao, Y.; Chen, Y.-C. *Angew. Chem. Int. Ed.* **2010**, *49*, 10189.
- (15) (a) Bencivenni, G.; Galzerano, P.; Mazzanti, A.; Bartoli, G.; Melchiorre, P. *Proc. Natl. Acad. Sci. U.S.A.* **2010**, *107*, 20642. (b) Bergonzini, G.; Vera, S.; Melchiorre, P. *Angew. Chem. Int. Ed.* **2010**, *49*, 9685. (c) Stiller, J.; Marqués-López, E.; Herrera, R. P.; Fröhlich, R.; Strohmman, C.; Christmann, M. *Org. Lett.* **2011**, *13*, 70. (d) Silvi, M.; Cassania, C.; Morana, A.; Melchiorre, P. *Helv. Chim. Acta* **2012**, *95*, 1985. (e) Bastida, D.; Liu, Y.; Tian, X.; Escudero-Adán, E.; Melchiorre, P. *Org. Lett.* **2013**, *15*, 220.
- (16) For a recent example of organocascade reaction involving dienamine catalysis, see: Appayee, C.; Fraboni, A. J.; Brenner-Moyer, S. E. *J. Org. Chem.* **2012**, *77*, 8828.
- (17) (a) Hong, B.-C.; Tseng, H.-C.; Chen, S.-H. *Tetrahedron* **2007**, *63*, 2840. (b) Hong, B.-C.; Wu, M.-F.; Tseng, H.-C.; Huang, G.-F.; Su, C.-F.; Liao, J.-H. *J. Org. Chem.* **2007**, *72*, 8459. (c) de Figueiredo, R. M.; Fröhlich, R.; Christmann, M. *Angew. Chem. Int. Ed.* **2008**, *47*, 1450. (d) Orue, A.; Reyes, E.; Vicario, J. L.; Carrillo, L.; Uribe, U. *Org. Lett.* **2012**, *14*, 3740. (e) Feng, X.; Zhou, Z.; Zhou, R.; Zhou, Q.-Q.; Dong, L.; Chen, Y.-C. *J. Am. Chem. Soc.* **2012**, *134*, 19942.
- (18) (a) Han, B.; He, Z.-Q.; Li, J.-L.; Li, R.; Jiang, K.; Liu, T.-Y.; Chen, Y.-C. *Angew. Chem. Int. Ed.* **2009**, *48*, 5474. For examples of inverse electron-demand Diels–Alder reactions, see: (b) Li, J.-L.; Kang, T.-R.; Zhou, S.-L.; Li, R.; Wu, L.; Chen, Y.-C. *Angew. Chem. Int. Ed.* **2010**, *49*, 6418. (c) Li, J.-L.; Zhou, S.-L.; Chen, P.-Q.; Dong, L.; Liu, T.-Y.; Chen, Y.-C. *Chem. Sci.* **2012**, *3*, 1879.
- (19) For examples of asymmetric organocatalytic formal [2+2]-cycloadditions, see: (a) Albrecht, L.; Dickmeiss, G.; Cruz Acosta, F.; Rodríguez-Escrich, C.; Davis, R. L.; Jørgensen, K. A. *J. Am. Chem. Soc.* **2012**, *134*, 2543. (b) Talavera, G.; Reyes, E.; Vicario, J. L.; Carrillo, L. *Angew. Chem. Int. Ed.* **2012**, *51*, 4104.
- (20) Rauhut, M. M.; Currier, H. US Patent 3,074,999, **1963**.
- (21) For a review on Rauhut–Currier reactions, see: Aroyan, C. E.; Dermenci, A.; Miller, S. J. *Tetrahedron* **2009**, *65*, 4069.
- (22) For reviews on Morita–Baylis–Hillman reaction, see: (a) Masson, G.; Houssemann, C.; Zhu, J. *Angew. Chem. Int. Ed.* **2007**, *46*, 4614. (b) Mansilla, J.; Saá, J. M. *Molecules* **2010**, *15*, 709. (c) Basavaiah, D.; Reddy, B. S.; Badsara, S. S. *Chem. Rev.* **2010**, *110*, 5447.
- (23) Erguden, J. K.; Moore, H. W. *Org. Lett.* **1999**, *1*, 375.
- (24) Wang, L.-C.; Luis, A. L.; Agapiou, K.; Jang, H.-Y.; Krische, M. J. *J. Am. Chem. Soc.* **2002**, *124*, 2402.
- (25) (a) Frank, S. A.; Mergott, D. J.; Roush, W. R. *J. Am. Chem. Soc.* **2002**, *124*, 2404. (b) Thalji, R. K.; Roush, W. R. *J. Am. Chem. Soc.* **2005**, *127*, 16778.
- (26) (a) Aroyan, C. E.; Miller, S. J. *J. Am. Chem. Soc.* **2007**, *129*, 256. (b) Aroyan, C. E.; Dermenci, A.; Miller, S. J. *J. Org. Chem.* **2010**, *75*, 5784. For an example of the application of the RC reaction in the synthesis of natural products, see: (c) Dermenci, A.; Selig, P. S.; Domoaal, R. A.; Spasov, K. A.; Anderson, K. S.; Miller, S. J. *Chem. Sci.* **2011**, *2*, 1568.
- (27) Gong, J.-J.; Li, T.-Z.; Pan, K.; Wu, X.-Y. *Chem. Commun.* **2011**, 47, 1491.
- (28) Wang, X.-F.; Peng, L.; An, J.; Li, C.; Yang, Q.-Q.; Lu, L.-Q.; Gu, F.-L.; Xiao, W.-J. *Chem. Eur. J.* **2011**, *17*, 6484.
- (29) (a) Takizawa, S.; Nguyen, T. M.-N.; Grossmann, A.; Enders, D.; Sasai, H. *Angew. Chem. Int. Ed.* **2012**, *51*, 5423. (b) Takizawa, S.; Nguyen, T. M.-N.; Grossmann,

- A.; Suzuki, M.; Enders, D.; Sasai, H. *Tetrahedron* **2013**, *69*, 1202.
- (30) Zhang, X.-N.; Shi, M. *Eur. J. Org. Chem.* **2012**, 6271.
- (31) Jin, Z.; Yang, R.; Du, Y.; Tiwari, B.; Ganguly, R.; Chi, Y. R. *Org. Lett.* **2012**, *14*, 3226.
- (32) For a non-organocatalyzed example, see: Seidel, F.; Gladysz, J. A. *Synlett* **2007**, 986.
- (33) For other examples of intramolecular non-chiral RC reaction, see: (a) Selig, P. S.; Miller, S. J. *Tetrahedron Lett.* **2011**, *52*, 2148. (b) MacKay, J. A.; Landis, Z. C.; Motika, S. E.; Kench, M. H. *J. Org. Chem.* **2012**, *77*, 7768.
- (34) (a) Zhong, C.; Chen, Y.; Petersen, J. L.; Akhmedov, N. G.; Shi, X. *Angew. Chem. Int. Ed.* **2009**, *48*, 1279. (b) Zhao, Q.-Y.; Pei, C.-K.; Guan, X.-Y.; Shi, M. *Adv. Synth. Cat.* **2011**, *353*, 1973. (c) Atienza, R. L.; Scheidt, K. A. *Aust. J. Chem.* **2011**, *64*, 1158. For an example of aza-Rauhut–Currier reactions, see: (d) Shi, Z.; Yu, P.; Loh, T.-P.; Zhong, G. *Angew. Chem. Int. Ed.* **2012**, *51*, 7825.
- (35) For selected examples of non-enantioselective intermolecular RC reaction, see: (a) Reynolds, T. E.; Binkley, M. S.; Scheidt, K. A. *Org. Lett.* **2008**, *10*, 2449. (b) Yao, W.; Wu, Y.; Wang, G.; Zhang, Y.; Ma, C. *Angew. Chem. Int. Ed.* **2009**, *48*, 9713. (c) Shanbhag, P.; Nareddy, P. R.; Dadwal, M.; Mobin, M. S.; Namboothiri, I. N. N. *Org. Biomol. Chem.* **2010**, *8*, 4867. For examples of non-enantioselective RC domino reactions, see: (d) Xie, P.; Huang, Y.; Lai, W.; Meng, X.; Chen, R. *Org. Biomol. Chem.* **2011**, *9*, 6707. (e) Ma, J.; Xie, P.; Hu, C.; Huang, Y.; Chen, R. *Chem. Eur. J.* **2011**, *17*, 7418. (f) Liu, W.; Zhou, J.; Zheng, C.; Chen, X.; Xiao, H.; Yang, Y.; Guo, Y.; Zhao, G. *Tetrahedron* **2011**, *67*, 1768. (g) Hu, C.; Geng, Z.; Ma, J.; Huang, Y.; Chen, R. *Chem. Asian J.* **2012**, *7*, 2032. For an example of aza-Rauhut–Currier, see: (h) Shi, Z.; Tong, Q.; Wen, W.; Leong, Y.; Zhong, G. *Chem. Eur. J.* **2012**, *18*, 9802.
- (36) For reviews on cyclopentenones, see: (a) Hudlicky, T.; Price, J. D. *Chem. Rev.* **1989**, *89*, 1467. (b) Hartley, R. C.; Caldwell, S. T. *J. Chem. Soc. Perkin Trans. I* **2000**, 477. (c) Heasley, B. *Eur. J. Org. Chem.* **2009**, 1477.
- (37) Tundis, R.; Loizzo, M. R.; Menichini, F.; Statti, G. A.; Menichini, F. *Mini-Rev. Med. Chem.* **2008**, *8*, 399.
- (38) Boros, C. A.; Stermitz, F. R. *J. Nat. Prod.* **1990**, *53*, 1055.
- (39) (a) Tietze, L.-F. *Angew. Chem. Int. Ed. Engl.* **1983**, *22*, 828. (b) Villasenor, I. M. *Antiinflamm. Antiallergy Agents Med. Chem.* **2007**, *6*, 307.
- (40) Kim, H. J.; Ruszczycky, M. W.; Choi, S.-h.; Liu, Y.-n.; Liu, H.-w. *Nature* **2011**, *473*, 109.
- (41) (a) Lorenz, M.; Boland, W.; Dettner, K. *Angew. Chem. Int. Ed. Engl.* **1993**, *32*, 912. (b) Weibel, D. B.; Oldham, N. J.; Feld, B.; Glombitza, G.; Dettner, K.; Boland, W. *Insect Biochem. Mol. Biol.* **2001**, *31*, 583. (c) Kunert, M.; Rahfeld, P.; Shaker, K. H.; Schneider, B.; David, A.; Dettner, K.; Pasteels, J. M.; Boland, W. *ChemBioChem* **2013**. DOI: 10.1002/cbic.201200689.
- (42) For references of the effect of Brønsted acids in Morita–Baylis–Hillman reaction, see: (a) Shi, M.; Liu, Y. *Org. Biomol. Chem.* **2006**, *4*, 1468. (b) Abermil, N.; Masson, G.; Zhu, J. *J. Am. Chem. Soc.* **2008**, *130*, 12596. (c) Yukawa, T.; Seelig, B.; Xu, Y.; Morimoto, H.; Matsunaga, S.; Berkessel, A.; Shibasaki, M. *J. Am. Chem. Soc.* **2010**, *132*, 11988.
- (43) Watanabe, K.; Takada, Y.; Matsuo, N.; Nishimura, H. *Biosci. Biotech. Biochem.* **1996**, *59*, 1979.
- (44) For the first total synthesis of (R)- and (S)-rotundial, see: Takikawa, H.; Yamazaki, Y.; Mori, K. *Eur. J. Org. Chem.* **1998**, 229.
- (45) See Experimental Section.
- (46) (a) Seebach, D.; Großelj, U.; Badine, D. M.; Schweizer, W. B.; Beck, A. K. *Helv. Chim. Acta* **2008**, *91*, 1999. (b) Großelj, U.; Schweizer, W. B.; Ebert, M.-O.; Seebach, D. *Helv. Chim. Acta* **2009**, *92*, 1.
- (47) For theoretical discussions concerning dienamine intermediates, see: Duarte, F. J. S.; Cabrita, E. J.; Frenking, G.; Santos, A. G. *Chem. Eur. J.* **2009**, *15*, 1734.
- (48) E/Z-Isomerization of the enol moiety of **5** could lead to an intramolecular attack of the iminium ion and to a dead end in the catalytic cycle.
- (49) Preparation of the ESI-HRMS sample: After 5 minutes of reaction 20 μ L of the reaction mixture were taken, and the solvent was evaporated. The residue was solved in CH₃CN (1 mL).
- (50) Schmid, M. B.; Zeitler, K.; Gschwind, R. M. *Angew. Chem. Int. Ed.* **2010**, *49*, 4997.
- (51) (a) Weinges, K.; Ziegler, H. J.; Maurer, W.; Schmidbauer, S. B. *Liebigs Ann. Chem.* **1993**, 1029. (b) Yamane, T.; Takahashi, M.; Ogasawara, K. *Synthesis* **1995**, 444.
- (52) (a) Amri, H.; Villieras, J. *Tetrahedron Lett.* **1987**, *28*, 5521. (b) Bouyssi, D.; Monteiore, N.; Balme, G. *Tetrahedron Lett.* **1999**, *40*, 1297.
- (53) Ohta, H.; Kobori, T.; Fujisawa, T. *J. Org. Chem.* **1977**, *42*, 1231.
- (54) Wilson, R. M.; Jen, W. S.; MacMillan, D. W. C. *J. Am. Chem. Soc.* **2005**, *127*, 11616.
- (55) X ray crystallographic analysis data for **27**. CCDC 813588 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
- (56) The absolute configuration for compounds **21a-b** and **27** was not assigned unambiguously.
- (57) For more details see Supporting Information.
- (58) The synthesis of the products as racemic mixtures were carried out using a mixture of both enantiomers of the catalyst [(S)-**IV**:(R)-**IV**] 1:1].
- (59) (a) Amri, H.; Rambaud, M.; Villieras, J. *Tetrahedron* **1990**, *46*, 3535. (b) Nagata, H.; Ogasawara, K. *Tetrahedron Lett.* **1999**, *40*, 6617.